Cresco Labs Inc.

Informe acción CNSX:CL

Capitalización de mercado: CA$476.8m

Cresco Labs Dividendos y recompras

Dividendo controles de criterios 0/6

Cresco Labs no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-0.003%

Rendimiento de la recompra

Rendimiento total para el accionista-0.003%
Rendimiento futuro de los dividendosn/a
Crecimiento de los dividendosn/a
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Ratio de pagon/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Actualización de narrativa Jul 02

CL: Expanded Ohio Dispensary Footprint Will Support Future Upside Potential

Analysts have adjusted their CA$ fair value estimate for Cresco Labs from about CA$2.42 to roughly CA$2.72, reflecting updated views on its revenue outlook, profit margins, discount rate and future P/E assumptions. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, the company’s second Ohio dispensary opening in the past month.
Actualización de narrativa Jun 18

CL: Texas License And Expanded Ohio Stores Will Support Upside Skewed Profile

Analysts have nudged their fair value estimate for Cresco Labs stock from about CA$2.25 to roughly CA$2.35 per share, reflecting updated assumptions around discount rates, revenue growth, and future P/E expectations. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second Ohio dispensary opening in the past month, bringing its footprint to eight locations in the state and 74 nationally.
Actualización de narrativa Jun 04

CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile

Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.
Actualización de narrativa May 05

CL: Lower P/E Expectations Will Support A More Upside Skewed Profile

Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.
Actualización de narrativa Apr 20

CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.
Actualización de narrativa Apr 05

CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.
Actualización de narrativa Mar 22

CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook

Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.
Actualización de narrativa Mar 07

CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook

Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.
Actualización de narrativa Feb 21

CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook

Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).
Artículo de análisis Feb 12

Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Cresco Labs Inc. ( CSE:CL ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...
Actualización de narrativa Feb 06

CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook

Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).
Actualización de narrativa Jan 23

CL: New German Entry Will Support Future Upside

Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.
Actualización de narrativa Jan 09

CL: German Entry And Higher Margins Will Support Future Upside

Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).
Actualización de narrativa Dec 15

CL: Expanded Retail And European Entry Will Support Stronger Profitability

Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).
Artículo de análisis Nov 26

Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%

Unfortunately for some shareholders, the Cresco Labs Inc. ( CSE:CL ) share price has dived 37% in the last thirty days...
Artículo de análisis Nov 08

Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Artículo de análisis Oct 12

Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking

Despite an already strong run, Cresco Labs Inc. ( CSE:CL ) shares have been powering on, with a gain of 35% in the last...
Artículo de análisis Sep 06

Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?

Key Insights Cresco Labs' estimated fair value is CA$3.23 based on 2 Stage Free Cash Flow to Equity Current share price...
Artículo de análisis Jul 31

Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking

Cresco Labs Inc. ( CSE:CL ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...
Artículo de análisis Jul 23

Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Artículo de análisis Jun 15

Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk

The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 30...
Artículo de análisis May 01

Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up

Cresco Labs Inc. ( CSE:CL ) shareholders would be excited to see that the share price has had a great month, posting a...
User avatar
Nueva narrativa Mar 29

Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand

Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.
Artículo de análisis Mar 07

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%

The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 27...
Artículo de análisis Jan 31

Is Cresco Labs (CSE:CL) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Artículo de análisis Dec 14

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

To the annoyance of some shareholders, Cresco Labs Inc. ( CSE:CL ) shares are down a considerable 28% in the last...
Artículo de análisis Oct 24

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

It's not a stretch to say that Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.8x right now seems...
Artículo de análisis Aug 11

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Investors in Cresco Labs Inc. ( CSE:CL ) had a good week, as its shares rose 3.4% to close at CA$2.15 following the...
Artículo de análisis Jul 17

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Key Insights Cresco Labs' estimated fair value is CA$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...
Artículo de análisis Jun 19

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Artículo de análisis Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 26...
Artículo de análisis Mar 16

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

The investors in Cresco Labs Inc. 's ( CSE:CL ) will be rubbing their hands together with glee today, after the share...
Artículo de análisis Mar 03

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. ( CSE:CL ) shareholders won't be pleased to see that the share price has had a very rough month...

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CL han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CL han aumentado.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Cresco Labs vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de CL con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (CL)n/a
Suelo de mercado 25% (CA)1.7%
Techo de mercado 25% (CA)5.4%
Media de la industria (Pharmaceuticals)2.0%
Analista de previsiones (CL) (hasta 3 años)n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CL en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CL en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.


Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de CL para determinar si sus pagos de dividendos están cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CL no ha comunicado ningún pago.


Descubre empresas que pagan buenos dividendos

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/07/20 06:14
Precio de las acciones al final del día2026/07/20 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Cresco Labs Inc. está cubierta por 11 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Luke HannanCanaccord Genuity